Home › Research › TREM2 and immune genetics
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target
Li RY, Qin Q, Yang HC, Wang YY, Mi YX, Yin YS, Wang M, Yu CJ et al.. Molecular neurodegeneration, 2022-06-03
Topic: Brain proteins, microglia and lab models
Plain-language summary
Triggering receptor expressed on myeloid cells 2 (TREM2) is a single-pass transmembrane immune receptor that is mainly expressed on microglia in the brain and macrophages in the periphery. Recent studies have identified TREM2 as a risk factor for Alzheimer's disease (AD). Increasing evidence has shown that TREM2 can affect lipid metabolism both in the central nervous system (CNS) and in the periphery.
What this study adds
Evidence grade: Low
This is a narrative review. This review gathers earlier research suggesting that TREM2, an immune receptor found mainly on the brain's microglia and on macrophages in the body, is a risk factor for Alzheimer's and helps control how fats are handled. In the brain, it is described as affecting cholesterol, myelin and phospholipid metabolism and pushing microglia into a "disease-associated" state; in the body, as influencing obesity and related conditions such as high cholesterol, atherosclerosis and fatty liver disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Li, R. Y., Qin, Q., Yang, H. C., Wang, Y. Y., Mi, Y. X., Yin, Y. S., et al. (2022). TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target. Molecular neurodegeneration. https://doi.org/10.1186/s13024-022-00542-y
Vancouver
Li RY, Qin Q, Yang HC, Wang YY, Mi YX, Yin YS, et al. TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target. Molecular neurodegeneration. 2022. doi:10.1186/s13024-022-00542-y. PMID: 35658903.
BibTeX
@article{li2022-35658903,
author = {Li, R. Y. and Qin, Q. and Yang, H. C. and Wang, Y. Y. and Mi, Y. X. and Yin, Y. S. and Wang, M. and Yu, C. J. and others},
title = {{TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target}},
journal = {Molecular neurodegeneration},
year = {2022},
doi = {10.1186/s13024-022-00542-y},
pmid = {35658903},
url = {https://doi.org/10.1186/s13024-022-00542-y}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Recent studies have identified TREM2 as a risk factor for Alzheimer's disease (AD).
- Increasing evidence has shown that TREM2 can affect lipid metabolism both in the central nervous system (CNS) and in the periphery.
- In the CNS, TREM2 affects the metabolism of cholesterol, myelin, and phospholipids and promotes the transition of microglia into a disease-associated phenotype.
- In the periphery, TREM2 influences lipid metabolism by regulating the onset and progression of obesity and its complications, such as hypercholesterolemia, atherosclerosis, and nonalcoholic fatty liver disease.
Why it matters
This review gathers earlier research suggesting that TREM2, an immune receptor found mainly on the brain's microglia and on macrophages in the body, is a risk factor for Alzheimer's and helps control how fats are handled. In the brain, it is described as affecting cholesterol, myelin and phospholipid metabolism and pushing microglia into a "disease-associated" state; in the body, as influencing obesity and related conditions such as high cholesterol, atherosclerosis and fatty liver disease. It presents TREM2 as a *potential* metabolic drug target and reports no new data or treatment results.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 202 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 33.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 4 / 6 | Cited 11.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 3 / 4 | Cited 169 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Yi Tang: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Chinese Academy of Sciences: institution h-index 1,801 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35658903) |
| Free to read | 2 / 2 | Free to read |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13024-022-00542-y
- PubMed: 35658903
- Original source →
- Free full text: Molecular Neurodegeneration →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 79.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.